LEADARTIS
LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies.
LEADARTIS
Social Links:
Industry:
Biopharma Biotechnology Product Research
Founded:
2013-01-01
Address:
Madrid, Madrid, Spain
Country:
Spain
Website Url:
http://www.leadartis.com
Total Employee:
1+
Status:
Active
Contact:
(+34) 911 916 763
Email Addresses:
[email protected]
Total Funding:
350 K EUR
Technology used in webpage:
SPF Google Analytics LetsEncrypt Apache Google Maps COVID-19 Apache 2.4 Google Analytics Classic Drupal Debian
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
VitaResc Biotech AG
VitaResc Biotech is a biotechnology company engaged in the development of proprietary products that selectively modulate.
Current Employees Featured
Founder
Investors List
SODENA
SODENA investment in Seed Round - LeadArtis
Official Site Inspections
http://www.leadartis.com
- Host name: vxhcf-24.srv.cat
- IP address: 134.0.11.84
- Location: Spain
- Latitude: 40.4172
- Longitude: -3.684
- Timezone: Europe/Madrid
More informations about "LeadArtis"
Leadartis - Leadartis
LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most …See details»
Our company - Leadartis
LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer. By creating new medicines, we can create hope …See details»
Strategy - Leadartis
LeadArtis aims to develop differentiated and innovative medicines with the potential to make a real difference to patients, and to create sustainable value for all its stakeholders.See details»
LeadArtis - Crunchbase Company Profile & Funding
LeadArtis develops proprietary therapeutic antibodies, including immune and oncology. They provide immunomodulatory therapies for the treatment of cancer. They also provide research …See details»
Leadartis Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Leadartis. Use the PitchBook Platform to explore the full profile.See details»
Leadartis - LinkedIn
Molecular Engineering for Health | LeadArtis is a company developing bispecific tumor targeted antibodies based on its highly innovative protein engineering platform Trimerbody®.See details»
LEADARTIS - Navarra Health Cluster
LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies, with higher multivalence and multispecificity than the …See details»
Leadartis - Products, Competitors, Financials, Employees, …
LeadArtis is a biopharmaceutical company focused on the development of proprietary therapeutic antibodies in the healthcare sector. Use the CB Insights Platform to explore Leadartis's full …See details»
LeadArtis - Crunchbase
LeadArtis is a biopharmaceutical company that develops proprietary therapeutic antibodies.See details»
Scientific Advisory Board - Leadartis
LeadArtis has involved a group of specialists as scientific advisors including experts in immune cell cytotoxic responses and extensive experience in cancer immunotherapy clinical trials …See details»
Laura Sanz Alcober - Scientific Advisor at LeadArtis - The Org
Co-Founder of LeadArtis and a Senior Scientist at the Molecular Immunology Unit in the Hospital Universitario Puerta de Hierro (Madrid).See details»
LeadArtis - Contacts, Employees, Board Members, Advisors & Alumni
LeadArtis has 1 current employee profile, Founder & CEO Juan Jose Perez Villar. LeadArtis is a biopharmaceutical company that develops proprietary therapeutic antibodies.See details»
LeadArtis - VentureRadar
Website: http://www.leadartis.com/ Develops proprietary therapeutic antibodies called Trimerbodies, offering higher multivalence and multispecificity than prevalent …See details»
Partnership - Leadartis
The plug-and-play nature of LeadArtis technology enables the rapid creation of more powerful, more effective antibodies by simply incorporating the binding domains of pre-existing …See details»
“Tumor-targeted costimulatory trimerbodies for cancer …
Jun 7, 2021 · Bispecific Hexavalent Trimerbodies (BHTs) are multi-valent bispecific costimulatory tumor targeted antibodies directed against two clinically validated targets, on effector T …See details»
Research programme: antibody therapeutics - LeadArtis
Fully human antibody therapeutics are being developed by LeadArtis using its proprietary Trimerbody® platform, for the treatment of cancer. Trimerbody® is a.See details»
LeadArtis - Funding, Financials, Valuation & Investors - Crunchbase
LeadArtis is a biopharmaceutical company that develops proprietary therapeutic antibodies.See details»
Collaborations & Publications - Leadartis
Leadartis is fully engaged in collaboration agreements with companies, excellence research centers and universities including: Selexis SA. A Swiss company engaged in GMP compliant …See details»
Research programme: tyrosine kinase inhibitors - Leadartis
Leadartis was developing small molecule tyrosine kinase inhibitors for the treatment of advance solid tumours. Preclinical development was underway in Spain.See details»
Grant from the Community of Madrid - Leadartis
Leadartis is a small biotechnological company in preclinical stage whose purpose is to develop molecules able to trigger safe, effective and long-lasting antitumoral immune responses in …See details»